You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 017830

✉ Email this page to a colleague

NDA 017830 describes LODOSYN, which is a drug marketed by Aton and is included in one NDA. It is available from two suppliers. Additional details are available on the LODOSYN profile page.

The generic ingredient in LODOSYN is carbidopa. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the carbidopa profile page.

Summary for 017830

Tradename:	LODOSYN
Applicant:	Aton
Ingredient:	carbidopa
Patents:	0

Medical Subject Heading (MeSH) Categories for 017830

Antiparkinson Agents
Aromatic Amino Acid Decarboxylase Inhibitors
Dopamine Agents

Suppliers and Packaging for NDA: 017830

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LODOSYN	carbidopa	TABLET;ORAL	017830	NDA	Bausch Health US, LLC	25010-711	25010-711-15	100 TABLET in 1 BOTTLE (25010-711-15)
LODOSYN	carbidopa	TABLET;ORAL	017830	NDA AUTHORIZED GENERIC	Oceanside Pharmaceuticals	68682-200	68682-200-25	100 TABLET in 1 BOTTLE (68682-200-25)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	25MG
Approval Date:	Approved Prior to Jan 1, 1982	TE:	AB	RLD:	Yes

Expired US Patents for NDA 017830

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982	⤷ Get Started Free	⤷ Get Started Free
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982	⤷ Get Started Free	⤷ Get Started Free
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.